Core Viewpoint - Yangjie Technology has terminated its original plan to acquire Better Electronics through a combination of issuing shares and cash payments, opting instead to pursue a cash acquisition plan [2][3]. Group 1: Acquisition Details - Yangjie Technology signed a cash acquisition intention agreement with six major shareholders of Better Electronics on July 2, 2025, indicating a shift to negotiate a cash purchase of all or part of Better Electronics' shares [3][11]. - The original acquisition plan involved issuing shares and cash to 67 parties for 100% of Better Electronics, but the new plan significantly reduces the number of parties involved to just six [7][8]. - The decision to terminate the original plan was influenced by the changing capital market environment and the inability to reach an agreement on the terms of the share issuance and cash payment [8]. Group 2: Financial Performance - Yangjie Technology reported a revenue of 6.033 billion yuan in 2024, a year-on-year increase of 11.53%, and a net profit of 1.002 billion yuan, up 8.50% [12]. - In the first quarter of 2025, the company continued its growth trajectory with a revenue of 1.579 billion yuan, representing an 18.90% increase year-on-year, and a net profit of 273 million yuan, up 51.22% [12]. Group 3: Market Position and Strategy - Better Electronics specializes in the research, production, and sales of power electronic protection components, which aligns with Yangjie Technology's strategic focus on over-voltage protection products [11]. - The acquisition is expected to enhance Yangjie Technology's market position and competitiveness in the downstream customer segment [11].

花旗：将腾讯音乐(01698.HK)目标价格从17美元上调至23美元。 ...

Core Viewpoint - The Hang Seng Tech Index experienced a significant decline, dropping nearly 2% during trading, with Alibaba Health seeing a drop of over 7% [1] Group 1 - The Hang Seng Tech Index's intraday performance indicates a bearish trend in the technology sector [1] - Alibaba Health's stock performance reflects broader market concerns, as it fell more than 7%, suggesting potential investor apprehension [1]

Core Viewpoint - The report from CICC maintains the profit forecast for Dekang Agriculture (02419) for 2025/26, with the current stock price corresponding to P/E ratios of 11.5 and 6.7 for those years. The target price is raised by 68% to HKD 111, indicating a potential upside of 28% from the current price, supported by the company's continued growth and improved trading liquidity [1] Group 1 - The company adopts a "company + farmer" light asset development model, with the second farm's sow breeding model achieving the lowest costs within the system. The current operational model distribution is 20% self-operated, 60% first farm, and 20% second farm, with the average annual income for contracted farmers reaching RMB 770,000, a historical high for the company [2] - The second farm model has lower breeding costs compared to the first farm and self-operated models, enhancing operational efficiency and farmer engagement [2] Group 2 - The company continues to reduce costs, maintaining its position as an industry leader. The monthly total cost is reported to be below RMB 12.5 per kilogram, attributed to a focused breeding strategy in the Southwest region, technological empowerment, and efficient management practices [3] - The company expects to achieve a pig output of 11 million and 15 million heads in 2025 and 2026, respectively, with long-term potential exceeding 30 million heads [3] Group 3 - Liquidity has improved significantly, with an average turnover rate of 1.9% since the release of the 2024 annual report, and average daily trading volume increasing to RMB 140 million from RMB 3.69 million year-on-year. The proportion of Hong Kong Stock Connect has also risen [4] - The valuation of the company is expected to increase, with a calculated average market value of RMB 2,528 per head, indicating a 22% potential increase compared to industry leaders [4]

Core Viewpoint - CICC maintains its profit forecast for Hutchison China MediTech (00013) at $360 million for 2025 and $100 million for 2026, with a target price of HKD 30, indicating a 20.5% upside from the current stock price [1] Group 1: Drug Approval and Market Potential - The recently approved indication for Savolitinib is the largest for the drug to date [2] - Approximately 10-25% of non-small cell lung cancer (NSCLC) patients in the US and Europe have EGFR mutations, while the rate is as high as 30-40% in Asian patients [2] - MET amplification is a major mechanism of acquired resistance in EGFR-mutant NSCLC patients, with 15-50% of patients showing MET abnormalities after third-generation EGFR TKI treatment [2] Group 2: Clinical Trial Results - The approval is based on the SACHI Phase III study, which showed significant progression-free survival (PFS) benefits compared to platinum-based chemotherapy [3] - In the SACHI intent-to-treat population, the median PFS for the Savolitinib + Osimertinib combination was 8.2 months and 7.2 months, compared to 4.5 months and 4.2 months for the chemotherapy group, reducing the risk of disease progression by 66% and 60% respectively [3] Group 3: Ongoing Clinical Trials and Regulatory Progress - The SAFFRON Phase III clinical trial is ongoing, focusing on regulatory registration progress overseas [4] - The combination therapy received Fast Track designation from the FDA in 2023, with AstraZeneca conducting the SAFFRON trial to evaluate its effectiveness against platinum-based doublet chemotherapy in MET-overexpressing NSCLC [4] - Attention is recommended on the data readout from SAFFRON in 2026 and the overseas application status [4]

Group 1: Regulatory Changes - Beijing's housing authority has proposed a notification to regulate individuals renting out 10 or more housing units, requiring them to register as market entities and file with housing management departments [1] Group 2: Real Estate Transactions - China State Construction Engineering Corporation acquired a land parcel in Beijing's Yanqing District for a base price of 560 million yuan, covering an area of approximately 22,300 square meters with a planned construction area of about 36,100 square meters [2] - Yuexiu Property reported a contract sales amount of approximately 10.8 billion yuan in June, representing a year-on-year decline of about 29.4%, with a sales area of approximately 293,000 square meters, down about 39.7% year-on-year [3] - Poly Developments disclosed a contract signing amount of 29.011 billion yuan in June, with a signed area of 1.5233 million square meters, reflecting a year-on-year decrease of 30.95% [5] Group 3: Financing Activities - Vanke A announced an application for a loan of up to 6.249 billion yuan from its largest shareholder, Shenzhen Metro Group, to repay bond principal and interest, with a loan term of no more than three years [4]

菲律宾央行：将通过确保货币政策有利于可持续经济增长和就业来维护物价稳定。 ...

Group 1 - The Hang Seng Index opened down 0.7%, with the Hang Seng Tech Index falling 0.75%. Alibaba Health dropped nearly 5%, and AIA Group fell nearly 2% [1] - According to Zhongtai International, the technical bull market pattern for Hong Kong stocks is clear in the first half of the year, with expectations for continued strength in the market under supportive policies and improved US dollar liquidity in the second half of 2025 [1] - Earnings per share for the Hang Seng Index are projected to grow by 8.5% and 8.3% in 2025 and 2026, respectively [1] Group 2 - CITIC Securities anticipates that the ongoing reform of the Hong Kong listing system will enhance the asset quality and liquidity of the market, with southbound capital likely to continue flowing into Hong Kong stocks [2] - The market is expected to show a trend of "oscillation upwards + structural differentiation" in the second half of the year, driven by macro policies focusing on high-quality development, technological innovation, and domestic demand [2] - Annual net inflow of southbound funds is expected to exceed 1 trillion yuan, continuously improving liquidity in the Hong Kong stock market [2]

Group 1 - The Hang Seng Index opened down by 0.7% and the Hang Seng Tech Index opened down by 0.75% [1] - Xiaopeng Motors (09868.HK) opened down nearly 2% following the launch of its first L3-level AI vehicle, the Xiaopeng G7 [1]

恒指低开0.70%，报23900.69点；恒生科技指数跌0.75%。阿里健康跌4.9%，小鹏汽车跌近2%，腾讯、 美团、网易、小米等跌超1%。 ...